{"hands_on_practices": [{"introduction": "Understanding how direct-acting antivirals (DAAs) function at the molecular level is the first step toward mastering their clinical use. This exercise focuses on the HCV NS3/4A protease, a critical enzyme for viral maturation and a prime target for a major class of DAAs. By applying the principles of competitive inhibition to a Michaelis-Menten kinetic model, you will derive the effect of a protease inhibitor on its target, gaining a quantitative appreciation for how these drugs achieve their potent antiviral effect. [@problem_id:4648913]", "problem": "Hepatitis C virus encodes the Nonstructural protein 3/4A (NS3/4A) serine protease that cleaves polyprotein junction peptides to enable viral maturation. In a cell-free kinetic assay with constant total protease concentration, assume NS3/4A-mediated cleavage of a single junction peptide follows a simple Michaelis–Menten mechanism with competitive inhibition by a Direct-Acting Antiviral (DAA) protease inhibitor. Adopt the standard mass-action enzyme scheme: free enzyme $E$ binds substrate $S$ to form $ES$ and converts $ES$ to product $P$, while the inhibitor $I$ binds the same free enzyme $E$ to form $EI$ and does not bind $ES$. Let the catalytic turnover be $k_{\\text{cat}}$, the Michaelis constant be $K_{m}$, the inhibition constant be $K_{i}$ defined by $K_{i} = \\frac{[E][I]}{[EI]}$ at rapid equilibrium, and the maximal velocity be $V_{\\max} = k_{\\text{cat}} E_{\\text{t}}$ where $E_{\\text{t}}$ is total enzyme concentration.\n\nStarting from these definitions and the steady-state approximation for $[ES]$, derive the expression for the initial processing rate $v$ as a function of substrate concentration $[S]$ and inhibitor concentration $[I]$ under competitive inhibition, and then compute the expected fractional decrease in processing rate due to the inhibitor, defined by\n$$D = 1 - \\frac{v_{\\text{inh}}}{v_{0}},$$\nwhere $v_{0}$ is the rate in the absence of inhibitor and $v_{\\text{inh}}$ is the rate at inhibitor concentration $[I]$.\n\nUse the following experimentally plausible parameters: $V_{\\max} = 2.5~\\mu\\mathrm{M}\\,\\mathrm{min}^{-1}$, $K_{m} = 8~\\mu\\mathrm{M}$, substrate concentration $[S] = 12~\\mu\\mathrm{M}$, inhibitor concentration $[I] = 40~\\mathrm{nM}$, and inhibition constant $K_{i} = 1~\\mathrm{nM}$. Ensure unit consistency in your calculation. Provide the final value of $D$ as a decimal number without a percent sign. Round your answer to four significant figures.", "solution": "The problem statement is subjected to validation before a solution is attempted.\n\n### Step 1: Extract Givens\nThe following information is provided in the problem statement:\n- **System**: Hepatitis C virus Nonstructural protein 3/4A (NS3/4A) serine protease.\n- **Mechanism**: Simple Michaelis-Menten kinetics with competitive inhibition by a Direct-Acting Antiviral (DAA).\n- **Kinetic Scheme**:\n    - Free enzyme $E$ binds substrate $S$ to form complex $ES$.\n    - $ES$ is converted to product $P$ and free enzyme $E$.\n    - Inhibitor $I$ binds to free enzyme $E$ to form complex $EI$.\n    - Inhibitor $I$ does not bind to the $ES$ complex.\n- **Assumptions**:\n    - Total protease concentration, $E_{\\text{t}}$, is constant.\n    - The steady-state approximation is valid for the concentration of the enzyme-substrate complex, $[ES]$.\n    - The binding of the inhibitor to the free enzyme is at rapid equilibrium.\n- **Definitions**:\n    - Catalytic turnover: $k_{\\text{cat}}$\n    - Michaelis constant: $K_{m}$\n    - Inhibition constant: $K_{i} = \\frac{[E][I]}{[EI]}$\n    - Maximal velocity: $V_{\\max} = k_{\\text{cat}} E_{\\text{t}}$\n- **Required Derivation**: An expression for the initial processing rate $v$ as a function of substrate concentration $[S]$ and inhibitor concentration $[I]$.\n- **Required Calculation**: The fractional decrease in processing rate, $D = 1 - \\frac{v_{\\text{inh}}}{v_{0}}$, where $v_{0}$ is the rate without inhibitor and $v_{\\text{inh}}$ is the rate with inhibitor at concentration $[I]$.\n- **Parameters**:\n    - $V_{\\max} = 2.5~\\mu\\mathrm{M}\\,\\mathrm{min}^{-1}$\n    - $K_{m} = 8~\\mu\\mathrm{M}$\n    - $[S] = 12~\\mu\\mathrm{M}$\n    - $[I] = 40~\\mathrm{nM}$\n    - $K_{i} = 1~\\mathrm{nM}$\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is based on the well-established Michaelis-Menten model of enzyme kinetics and its extension to competitive inhibition. This is a cornerstone of biochemistry. The application to the HCV NS3/4A protease and DAAs is a canonical example used in virology and drug development. The problem is scientifically sound.\n- **Well-Posed**: The problem asks for a standard derivation followed by a calculation using a complete set of parameters. A unique and meaningful solution exists.\n- **Objective**: The language is formal, precise, and devoid of subjectivity.\n- **Incomplete or Contradictory Setup**: The problem provides all necessary definitions, constants, and concentrations. There are no contradictions.\n- **Unrealistic or Infeasible**: The given kinetic parameters ($K_m$, $K_i$) and concentrations ($[S]$, $[I]$) are experimentally plausible for a potent protease inhibitor.\n- **Ill-Posed or Poorly Structured**: The problem is clearly structured, asking for a derivation and then a calculation.\n\n### Step 3: Verdict and Action\nThe problem is deemed **valid**. It is a standard, well-posed problem in enzyme kinetics. A full solution will be provided.\n\n### Solution Derivation\nThe enzymatic reaction scheme under competitive inhibition is described by two coupled equilibria and one irreversible catalytic step:\n$$E + S \\underset{k_{-1}}{\\stackrel{k_1}{\\rightleftharpoons}} ES \\stackrel{k_{\\text{cat}}}{\\longrightarrow} E + P$$\n$$E + I \\underset{k_{-i}}{\\stackrel{k_i}{\\rightleftharpoons}} EI$$\nThe initial velocity of the reaction, $v$, is the rate of product formation:\n$$v = \\frac{d[P]}{dt} = k_{\\text{cat}}[ES]$$\nThe total enzyme concentration, $E_{\\text{t}}$, is constant and is partitioned among the free enzyme, the enzyme-substrate complex, and the enzyme-inhibitor complex:\n$$E_{\\text{t}} = [E] + [ES] + [EI]$$\nThe problem states to use the steady-state approximation for $[ES]$, which implies that its concentration does not change over the initial period of the reaction:\n$$\\frac{d[ES]}{dt} = k_{1}[E][S] - (k_{-1} + k_{\\text{cat}})[ES] = 0$$\nFrom this, we can write:\n$$k_{1}[E][S] = (k_{-1} + k_{\\text{cat}})[ES]$$\nRecalling the definition of the Michaelis constant, $K_{m} = \\frac{k_{-1} + k_{\\text{cat}}}{k_1}$, we can rearrange the steady-state equation to express the free enzyme concentration $[E]$ in terms of $[ES]$:\n$$[E] = \\frac{K_{m}[ES]}{[S]}$$\nThe inhibitor binding is defined to be at rapid equilibrium, governed by the inhibition constant $K_{i}$:\n$$K_{i} = \\frac{[E][I]}{[EI]}$$\nThis allows us to express the concentration of the enzyme-inhibitor complex, $[EI]$, in terms of $[E]$ and $[I]$:\n$$[EI] = \\frac{[E][I]}{K_{i}}$$\nNow, we substitute the expressions for $[E]$ and $[EI]$ into the enzyme conservation equation:\n$$E_{\\text{t}} = \\left(\\frac{K_{m}[ES]}{[S]}\\right) + [ES] + \\left(\\frac{[E][I]}{K_{i}}\\right)$$\nReplace the remaining $[E]$ in the third term:\n$$E_{\\text{t}} = \\frac{K_{m}[ES]}{[S]} + [ES] + \\frac{\\left(\\frac{K_{m}[ES]}{[S]}\\right)[I]}{K_{i}}$$\nFactor out $[ES]$:\n$$E_{\\text{t}} = [ES] \\left( \\frac{K_{m}}{[S]} + 1 + \\frac{K_{m}[I]}{[S]K_{i}} \\right)$$\n$$E_{\\text{t}} = [ES] \\left( \\frac{K_{m} + [S] + \\frac{K_{m}[I]}{K_{i}}}{[S]} \\right)$$\nSolve for $[ES]$:\n$$[ES] = \\frac{E_{\\text{t}}[S]}{K_{m} + [S] + \\frac{K_{m}[I]}{K_{i}}} = \\frac{E_{\\text{t}}[S]}{K_{m}\\left(1 + \\frac{[I]}{K_{i}}\\right) + [S]}$$\nFinally, we substitute this expression for $[ES]$ into the rate equation $v = k_{\\text{cat}}[ES]$. Using the definition $V_{\\max} = k_{\\text{cat}}E_{\\text{t}}$, we arrive at the rate equation for competitive inhibition, which we denote as $v_{\\text{inh}}$:\n$$v_{\\text{inh}} = \\frac{k_{\\text{cat}}E_{\\text{t}}[S]}{K_{m}\\left(1 + \\frac{[I]}{K_{i}}\\right) + [S]} = \\frac{V_{\\max}[S]}{K_{m}\\left(1 + \\frac{[I]}{K_{i}}\\right) + [S]}$$\nThis completes the first part of the problem.\n\nNext, we compute the fractional decrease in processing rate, $D = 1 - \\frac{v_{\\text{inh}}}{v_{0}}$.\nThe rate in the absence of inhibitor, $v_{0}$, is found by setting $[I]=0$ in the above equation, which yields the standard Michaelis-Menten equation:\n$$v_{0} = \\frac{V_{\\max}[S]}{K_{m} + [S]}$$\nThe ratio $\\frac{v_{\\text{inh}}}{v_{0}}$ is therefore:\n$$\\frac{v_{\\text{inh}}}{v_{0}} = \\frac{\\frac{V_{\\max}[S]}{K_{m}\\left(1 + \\frac{[I]}{K_{i}}\\right) + [S]}}{\\frac{V_{\\max}[S]}{K_{m} + [S]}} = \\frac{K_{m} + [S]}{K_{m}\\left(1 + \\frac{[I]}{K_{i}}\\right) + [S]} = \\frac{K_{m} + [S]}{K_{m} + [S] + \\frac{K_{m}[I]}{K_{i}}}$$\nNow, we substitute this ratio into the definition of $D$:\n$$D = 1 - \\frac{v_{\\text{inh}}}{v_{0}} = 1 - \\frac{K_{m} + [S]}{K_{m} + [S] + \\frac{K_{m}[I]}{K_{i}}}$$\n$$D = \\frac{\\left(K_{m} + [S] + \\frac{K_{m}[I]}{K_{i}}\\right) - (K_{m} + [S])}{K_{m} + [S] + \\frac{K_{m}[I]}{K_{i}}}$$\n$$D = \\frac{\\frac{K_{m}[I]}{K_{i}}}{K_{m} + [S] + \\frac{K_{m}[I]}{K_{i}}}$$\n\n### Numerical Calculation\nThe given parameters are:\n$K_{m} = 8~\\mu\\mathrm{M}$\n$[S] = 12~\\mu\\mathrm{M}$\n$[I] = 40~\\mathrm{nM}$\n$K_{i} = 1~\\mathrm{nM}$\n\nFor consistency, all concentrations must be in the same units. We can work with either $\\mu\\mathrm{M}$ or $\\mathrm{nM}$. The ratio $\\frac{[I]}{K_{i}}$ is unitless, so we can calculate it directly:\n$$\\frac{[I]}{K_{i}} = \\frac{40~\\mathrm{nM}}{1~\\mathrm{nM}} = 40$$\nNow we can substitute the values into the derived expression for $D$. Note that the units of $K_m$ and $[S]$ are both $\\mu\\mathrm{M}$, ensuring consistency in the denominator.\n$$D = \\frac{K_{m} \\left(\\frac{[I]}{K_{i}}\\right)}{K_{m} + [S] + K_{m} \\left(\\frac{[I]}{K_{i}}\\right)}$$\n$$D = \\frac{8~\\mu\\mathrm{M} \\times 40}{8~\\mu\\mathrm{M} + 12~\\mu\\mathrm{M} + 8~\\mu\\mathrm{M} \\times 40}$$\n$$D = \\frac{320~\\mu\\mathrm{M}}{20~\\mu\\mathrm{M} + 320~\\mu\\mathrm{M}}$$\n$$D = \\frac{320~\\mu\\mathrm{M}}{340~\\mu\\mathrm{M}} = \\frac{320}{340} = \\frac{32}{34} = \\frac{16}{17}$$\nTo provide the answer as a decimal number, we perform the division:\n$$D = \\frac{16}{17} \\approx 0.94117647...$$\nRounding to four significant figures as required by the problem statement gives:\n$$D \\approx 0.9412$$\nThis result indicates that the specified concentration of the inhibitor reduces the enzyme's processing rate by approximately $94.12\\%$.", "answer": "$$\\boxed{0.9412}$$", "id": "4648913"}, {"introduction": "While DAAs are powerful, the hepatitis C virus possesses a formidable counter-strategy: rapid evolution. HCV replicates with an error-prone polymerase, generating a vast and diverse population of viral variants, or a 'quasispecies,' within a single host. This practice problem demonstrates the sheer scale of this mutational capacity by calculating the expected number of new mutants arising in a single replication cycle. [@problem_id:4648944] Understanding this principle is crucial for appreciating why drug resistance is a constant threat and a central challenge in antiviral therapy.", "problem": "Within a single host infected with hepatitis C virus (HCV), consider a large, well-mixed population of viral genomes undergoing one round of replication. A direct-acting antiviral (DAA) targets a single codon in a nonstructural protein, and resistance can be initiated by a single-nucleotide change at a specific site within that codon. Assume each genome replicates once per round and that mutations at this site arise independently across genomes. The per-base mutation rate is defined as the probability per replication event that a given nucleotide site undergoes a single-nucleotide substitution. Let the per-base mutation rate be $\\mu=10^{-5}$ and the number of replicating genomes per round be $N=10^{9}$. Using only the foundational definition of per-base mutation rate and independence across genomes, derive the expected number of single-nucleotide mutants at that specific site generated in one replication round and compute its value. Express your final answer as an exact integer count with no units.", "solution": "The user wants me to solve a problem based on the provided text.\n\nFirst, I will validate the problem statement.\n\n**Step 1: Extract Givens**\n- The system is a large, well-mixed population of hepatitis C virus (HCV) genomes in a single host undergoing one round of replication.\n- Resistance to a direct-acting antiviral (DAA) is initiated by a single-nucleotide change at a specific site.\n- Each genome replicates once per round.\n- Mutations at the specific site arise independently across genomes.\n- The per-base mutation rate, $\\mu$, is the probability per replication event that a given nucleotide site undergoes a single-nucleotide substitution.\n- Value of per-base mutation rate: $\\mu = 10^{-5}$.\n- Number of replicating genomes per round: $N = 10^{9}$.\n- The task is to derive the expected number of single-nucleotide mutants at the specific site generated in one replication round and compute its value.\n- The derivation must use only the foundational definition of the per-base mutation rate and the principle of independence across genomes.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientifically Grounded:** The problem is grounded in fundamental principles of virology and population genetics. HCV is an RNA virus known for its high genetic variability, driven by a high mutation rate of its RNA-dependent RNA polymerase. The given mutation rate, $\\mu = 10^{-5}$ per base per replication, and the viral population size, $N = 10^{9}$ genomes, are biologically plausible orders of magnitude for an *in vivo* HCV infection. The mechanism of DAA resistance arising from single-nucleotide polymorphisms is a well-established clinical and virological reality. The problem is scientifically sound.\n- **Well-Posed:** The problem is well-posed. It asks for the expected value of a random variable (the number of mutants), providing all necessary parameters ($N$ and $\\mu$) and a clear set of assumptions (independence, one replication event per genome). A unique, stable, and meaningful solution can be determined.\n- **Objective:** The problem is stated in precise, objective language. It defines terms clearly and presents a quantitative question without any subjective or opinion-based elements.\n- **Flaw Check:**\n  - 1. Scientific/Factual Unsoundness: None.\n  - 2. Non-Formalizable/Irrelevant: None. The problem is a direct and formalizable application of probability theory to virology.\n  - 3. Incomplete/Contradictory Setup: None. All necessary information is provided.\n  - 4. Unrealistic/Infeasible: None. The parameters are within realistic biological ranges.\n  - 5. Ill-Posed/Poorly Structured: None. The question is unambiguous.\n  - 6. Pseudo-Profound/Trivial: While the underlying calculation is straightforward, the problem correctly frames it as a derivation from first principles, which is a valid pedagogical approach. It is not trivial or tautological.\n  - 7. Outside Scientific Verifiability: None. The result is mathematically derivable and verifiable.\n\n**Step 3: Verdict and Action**\n- The problem is **valid**. The solution process will proceed.\n\n**Solution Derivation**\nThe problem asks for the expected number of viral genomes that acquire a single-nucleotide mutation at a specific site during one round of replication.\n\nLet $N$ be the total number of replicating genomes, where $N = 10^{9}$.\nLet $\\mu$ be the per-base mutation rate, which is the probability that a mutation occurs at the specific site for a single genome during its one replication event. Here, $\\mu = 10^{-5}$.\n\nWe can model the mutation event for each genome as a Bernoulli trial. Let us define an indicator random variable $X_i$ for each genome $i$, where $i$ ranges from $1$ to $N$.\nThe variable $X_i$ is defined as:\n$X_i = 1$ if the $i$-th genome acquires a mutation at the specific site.\n$X_i = 0$ if the $i$-th genome does not acquire a mutation at the specific site.\n\nAccording to the problem's definition of the per-base mutation rate, the probability of a mutation for a single genome is $P(X_i = 1) = \\mu$.\nConsequently, the probability of no mutation is $P(X_i = 0) = 1 - \\mu$.\n\nThe expected value of a single Bernoulli random variable $X_i$ is given by:\n$$E[X_i] = 1 \\cdot P(X_i = 1) + 0 \\cdot P(X_i = 0) = 1 \\cdot \\mu + 0 \\cdot (1 - \\mu) = \\mu$$\n\nThe total number of mutants in the population, let's call this random variable $M$, is the sum of the outcomes for all $N$ individual genomes:\n$$M = \\sum_{i=1}^{N} X_i$$\n\nThe problem asks for the expected number of mutants, which is the expected value of $M$, denoted as $E[M]$.\nA fundamental property of expectation is the linearity of expectation, which states that the expected value of a sum of random variables is the sum of their individual expected values. This property holds regardless of whether the variables are independent.\n$$E[M] = E\\left[\\sum_{i=1}^{N} X_i\\right] = \\sum_{i=1}^{N} E[X_i]$$\n\nSince each genome has the same probability of mutation $\\mu$, the expected value $E[X_i]$ is the same for all $i$.\n$$E[X_i] = \\mu \\quad \\text{for all } i \\in \\{1, 2, \\dots, N\\}$$\n\nSubstituting this into the sum:\n$$E[M] = \\sum_{i=1}^{N} \\mu = N \\mu$$\nThis derivation uses only the definition of the mutation rate as a probability and the fundamental properties of expectation, satisfying the problem's constraint. The assumption of independence would be required to determine the full probability distribution of $M$ (which would be a binomial distribution, $M \\sim B(N, \\mu)$), but is not strictly necessary to find the expected value, due to the linearity of expectation.\n\nNow, we compute the numerical value using the provided data:\n$N = 10^{9}$\n$\\mu = 10^{-5}$\n\nThe expected number of mutants is:\n$$E[M] = N \\mu = (10^{9}) \\times (10^{-5}) = 10^{9-5} = 10^{4}$$\nTherefore, the expected number of single-nucleotide mutants generated in one replication round is $10000$.", "answer": "$$\\boxed{10000}$$", "id": "4648944"}, {"introduction": "The constant generation of mutations means that drug-resistant variants can exist in a patient even before therapy begins. These pre-existing resistance-associated substitutions (RASs) can significantly impact treatment outcomes, making their detection a key part of modern HCV management. This final exercise translates the theoretical concept of mutation into a practical clinical scenario, asking you to calculate the expected number of patients with a specific RAS in a study cohort. [@problem_id:4648912] This demonstrates how population-level data on resistance prevalence directly informs clinical trial design and personalized treatment strategies.", "problem": "A clinical trial is being planned to evaluate first-line regimens containing Nonstructural protein 5A (NS5A) inhibitors among patients infected with hepatitis C virus (HCV) genotype 3. Prior to therapy, investigators assess the baseline prevalence of the resistance-associated substitution (RAS) Y93H in the population. Assume the following scientifically grounded setup:\n\n- The baseline prevalence of Y93H in genotype 3 is $10\\%$, meaning the probability that any given genotype 3 patient carries Y93H at baseline is $p = 0.10$.\n- A cohort of $n = 500$ genotype 3 patients is enrolled.\n- Each patient’s Y93H status is modeled as a Bernoulli trial with success probability $p$ (carriage of Y93H), and the cohort-level count of Y93H carriers is the sum of these Bernoulli variables.\n\nUsing only foundational probability definitions and principles common to epidemiology and infectious diseases (for example, the definition of prevalence as a probability and the standard properties of expectations for sums of indicator variables), determine the expected number of patients in this cohort who carry the Y93H RAS at baseline. Express your result as a count in the unit \"patients\" and round your answer to three significant figures.", "solution": "The problem statement must first be subjected to a rigorous validation process.\n\n### Step 1: Extract Givens\n- The context is a clinical trial evaluating first-line regimens for hepatitis C virus (HCV) genotype 3.\n- The resistance-associated substitution (RAS) of interest is Y93H in the Nonstructural protein 5A (NS5A) region.\n- The baseline prevalence of Y93H in genotype 3 is $10\\%$.\n- The probability that any given genotype 3 patient carries Y93H at baseline is $p = 0.10$.\n- A cohort of $n = 500$ genotype 3 patients is enrolled.\n- Each patient’s Y93H status is modeled as a Bernoulli trial with success probability $p$.\n- The cohort-level count of Y93H carriers is the sum of these Bernoulli variables.\n- The objective is to determine the expected number of patients carrying the Y93H RAS.\n- The result must be rounded to three significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded (Critical):** The problem is scientifically sound. The context of HCV, genotype 3, NS5A inhibitors, and the Y93H RAS is a standard and well-documented topic in clinical virology and hepatology. The given prevalence of $p = 0.10$ for Y93H in untreated genotype 3 patients is consistent with published epidemiological data. The modeling approach is a standard application of probability theory in biostatistics.\n- **Well-Posed:** The problem is well-posed. It provides all necessary information—the sample size ($n$) and the probability of the event ($p$)—to calculate the expected value. A unique and meaningful solution exists.\n- **Objective (Critical):** The problem is stated in precise, quantitative, and objective language. It is free from ambiguity, subjectivity, or opinion.\n\nThe problem does not exhibit any flaws. It is not scientifically unsound, non-formalizable, incomplete, unrealistic, ill-posed, or trivial. It is a straightforward application of fundamental probability principles to a realistic clinical scenario.\n\n### Step 3: Verdict and Action\nThe problem is valid. A complete solution will be provided.\n\n### Solution\nLet $n$ be the total number of patients in the cohort, where $n = 500$.\nLet $p$ be the probability that a single patient carries the Y93H RAS, where $p = 0.10$.\n\nTo formalize the problem from first principles, we define a set of random variables, $X_i$, for each patient $i$ where $i = 1, 2, \\dots, n$. Each $X_i$ is an indicator variable that represents the Y93H status of patient $i$. Specifically:\n$X_i = 1$ if patient $i$ carries the Y93H RAS.\n$X_i = 0$ if patient $i$ does not carry the Y93H RAS.\n\nThe problem states that each patient's status is a Bernoulli trial. The probability mass function of each $X_i$ is therefore:\n$$P(X_i = 1) = p = 0.10$$\n$$P(X_i = 0) = 1 - p = 1 - 0.10 = 0.90$$\n\nThe expected value of a single Bernoulli random variable, $E[X_i]$, is calculated from the definition of expectation for a discrete random variable:\n$$E[X_i] = \\sum_{k} k \\cdot P(X_i = k)$$\nFor the variable $X_i$, the possible values for $k$ are $0$ and $1$.\n$$E[X_i] = (1 \\cdot P(X_i = 1)) + (0 \\cdot P(X_i = 0))$$\n$$E[X_i] = (1 \\cdot p) + (0 \\cdot (1-p)) = p$$\n\nThe total number of patients in the cohort who carry the Y93H RAS, which we will denote as $X$, is the sum of these individual indicator variables:\n$$X = \\sum_{i=1}^{n} X_i$$\n\nThe problem asks for the expected number of patients carrying the RAS, which is the expected value of $X$, denoted $E[X]$. We use the property of linearity of expectation, which states that the expectation of a sum of random variables is the sum of their individual expectations:\n$$E[X] = E\\left[\\sum_{i=1}^{n} X_i\\right] = \\sum_{i=1}^{n} E[X_i]$$\n\nSince each patient is drawn from the same population, the expectation $E[X_i]$ is the same for all $i$ and is equal to $p$.\n$$E[X] = \\sum_{i=1}^{n} p$$\nThis is a sum of a constant, $p$, added to itself $n$ times.\n$$E[X] = n \\cdot p$$\n\nThis derivation shows that the expected value of a Binomial random variable (which $X$ is, as it is a sum of i.i.d. Bernoulli trials) is the product of the number of trials and the probability of success, derived from foundational principles as requested.\n\nNow, we substitute the given numerical values into the derived formula:\n$$n = 500$$\n$$p = 0.10$$\n$$E[X] = 500 \\times 0.10 = 50$$\n\nThe problem requires the answer to be rounded to three significant figures. The calculated exact value is $50$. To express this integer with three significant figures, we must add a decimal point and a trailing zero, representing the precision of the result as specified.\n$$E[X] = 50.0$$\nThis is the expected number of patients in the cohort who carry the Y93H RAS.", "answer": "$$\\boxed{50.0}$$", "id": "4648912"}]}